Healthy Extracts Reports Preliminary 2025 Results, Net Revenue Expected Up 45% to Record $4.5 Million

Rhea-AI Summary

Healthy Extracts (OTCQB:GELS) reported preliminary unaudited 2025 results showing net revenue up 45% to $4.5 million, driven by the Gummy USA merger, product launches, and channel expansion. Organic operations grew ~25% and subscription channels rose substantially, while management projects the new facility could reach a $20 million annual capacity in 2026.

Results are preliminary and subject to audit and revision before the company's Form 10-K filing.

AI-generated analysis. Not financial advice.

Positive

• Net revenue +45% to $4.5M in 2025
• Organic revenue +25% from existing operations
• Subscription customers +47%, Amazon Subscribe & Save +36%
• Gummy USA merger adds HACCP, GMP FDA-registered facility
• Manufacturing capacity potential of $20M annual revenue

Negative

• 2025 results are preliminary unaudited estimates subject to revision
• Current revenue ($4.5M) is ~4x below projected $20M facility capacity

News Market Reaction – GELS

-8.04%

4 alerts

-8.04% News Effect

-6.0% Trough Tracked

-$639K Valuation Impact

$7.30M Market Cap

1.2x Rel. Volume

On the day this news was published, GELS declined 8.04%, reflecting a notable negative market reaction. Argus tracked a trough of -6.0% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $639K from the company's valuation, bringing the market cap to $7.30M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

2025 net revenue: $4.5 million Net revenue growth: 45% Subscription growth: 47% +5 more

8 metrics

2025 net revenue $4.5 million Expected record net revenue for 2025

Net revenue growth 45% Expected year-over-year increase in 2025 net revenue

Subscription growth 47% 2025 increase in direct-to-consumer product subscriptions

Amazon Subscribe & Save growth 36% 2025 increase in Amazon subscription customers

Follow-on gummy order 6 million gummies Follow-on nutraceutical gummy order from women’s health client

Global gummy market $13 billion Size of global gummy supplement market referenced

Digestive health market $105 billion Projected 2033 digestive health products market size

Potential annual revenue More than $20 million Management’s targeted annualized revenue run-rate by year end

Market Reality Check

Price: $0.4930 Vol: Volume 22,916 vs 20-day a...

high vol

$0.4930 Last Close

Volume Volume 22,916 vs 20-day average 13,199 (relative volume 1.74×) indicates elevated trading interest ahead of/around this update. high

Technical Shares at $0.7384 are trading below the $1.19 200-day MA and remain 82.03% under the 52-week high, though about 15.36% above the 52-week low.

Peers on Argus

GELS showed a 11.71% gain while the momentum scanner only flagged one peer (SBFM...

1 Down

GELS showed a 11.71% gain while the momentum scanner only flagged one peer (SBFM) moving down about 5.02%. With no broad peer participation and mixed moves across listed healthcare peers, trading appears more company-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 11	Manufacturing partnership	Positive	-1.4%	MOU with Healthy Extracts for U.S. manufacturing and global distribution.
Jan 13	Preclinical CBD data	Positive	+6.4%	Preclinical data showing >22% CBD bioavailability increase vs oil product.
Dec 16	Asia sports partnership	Positive	+0.1%	Hong Kong Flag Football partnership plus China deal with $1.3M commitments.
Dec 09	China sales agreement	Positive	-0.9%	Three‑year Shenzhen Mana agreement with minimum ~$1.3M revenue expectation.
Dec 05	Preclinical delivery data	Positive	-0.9%	Preclinical study showing 300% early bioavailability and >20% higher absorption.

Pattern Detected

News has often been positive, but price reactions have been mixed, with several positive R&D and partnership updates seeing flat-to-negative moves and only some clinical data driving clearer upside.

Recent Company History

Over the past several months, Gelteq has focused on advancing its gel-based delivery technology and commercial footprint. Preclinical updates in Dec 2025 and Jan 2026 highlighted enhanced bioavailability for oil‑soluble drugs and cannabinoids, with one update prompting a 6.44% gain but others drawing muted or negative reactions. Commercially, the company signed a three‑year China sales agreement with minimum commitments of about $1.3 million and added a Hong Kong sports partnership. A February 2026 manufacturing and distribution MOU with Healthy Extracts set the stage for the deeper collaboration referenced in today’s announcement.

Market Pulse Summary

The stock moved -8.0% in the session following this news. A negative reaction despite strong growth ...

Analysis

The stock moved -8.0% in the session following this news. A negative reaction despite strong growth commentary would fit the pattern where several positive Gelteq updates led to flat or negative moves, as seen around prior preclinical and partnership news. Even with targeted revenue of $4.5 million for 2025 and expansion initiatives, investors have previously focused on balance sheet and going‑concern disclosures. Trading well below the $1.19 200‑day MA and 82.03% under the 52‑week high could have reinforced caution during any selloff.

Key Terms

nutraceutical, haccp, gmp-certified, fda-registered, +4 more

8 terms

nutraceutical medical

"a leader in nutraceutical innovations and precision dose gummy manufacturing"

A nutraceutical is a product made from food ingredients that is promoted to provide health benefits beyond basic nutrition — for example vitamins, herbal extracts, fortified foods, and dietary supplements. Investors watch nutraceuticals because they sit between food and medicine: consumer demand, limited regulation, and claims about health effects can drive fast sales and higher margins but also create liability, regulatory risk, and uncertainty about long‑term efficacy, which affect company value.

haccp technical

"The merger added Gummy USA's HACCP, GMP-certified and FDA-registered manufacturing facility"

A food safety management system that identifies potential hazards in production and sets specific checkpoints and actions to prevent contamination or spoilage, like a step-by-step kitchen checklist that stops problems before a dish reaches the table. For investors, HACCP compliance reduces the risk of costly recalls, regulatory penalties and reputational damage, and signals that a company has controls in place to protect product quality and supply-chain stability.

gmp-certified technical

"The merger added Gummy USA's HACCP, GMP-certified and FDA-registered manufacturing facility"

GMP-certified means a manufacturer has been inspected and approved for following Good Manufacturing Practice rules that ensure products are made consistently, safely, and meet quality standards. Think of it like a professional kitchen that follows strict recipes, cleanliness rules and checks so meals are safe every time. For investors, GMP certification lowers regulatory and product-risk, supports market access and brand trust, and can reduce the chance of costly recalls or production shutdowns.

fda-registered regulatory

"The merger added Gummy USA's HACCP, GMP-certified and FDA-registered manufacturing facility"

An FDA-registered facility or product is one that has been listed with the U.S. Food and Drug Administration as required for certain medical devices, manufacturers, or establishments — like being entered in an official government directory. It does not mean the FDA has approved or certified safety or effectiveness, but it does mean the operation is subject to inspections and regulatory rules, which affects market access, investor risk assessment, and credibility with customers and partners.

prebiotic medical

"fiber prebiotic and probiotic delivery straw"

Non-digestible ingredients that selectively feed beneficial bacteria in the gut, helping maintain a healthy microbial balance much like fertilizer helps desired plants in a garden. Investors care because prebiotics drive product demand, influence labeling and regulatory scrutiny, and can require clinical evidence to support health claims—factors that affect sales potential, research costs, and competitive positioning in food, supplement, and medical markets.

probiotic medical

"fiber prebiotic and probiotic delivery straw"

Live microorganisms, most often bacteria or yeast, that are added to foods or supplements to support digestion and overall gut health — think of them as friendly tenants brought into a crowded apartment building to restore balance. Investors watch probiotics because consumer demand, scientific evidence, labeling rules and safety data directly affect product sales, regulatory risk and a company’s valuation, so study results or policy changes can move stock prices.

form 10-k regulatory

"audited 2025 results to be filed in Form 10-K with the SEC"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

nasdaq uplisting regulatory

"on track to further enhance shareholder value with our planned Nasdaq uplisting"

A Nasdaq uplisting is when a company moves its stock from a smaller trading venue or a lower-tier listing to one of Nasdaq’s primary markets, after meeting stronger financial, governance and reporting standards. For investors it matters because uplisting can increase a stock’s visibility, trading volume and perceived credibility—similar to a small shop moving into a busy mall—potentially making shares easier to buy or sell and improving access to capital for the company.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Strong Annual Results Driven by Record-Setting Revenues for Fifth Quarter in a Row, Setting Stage for Another Record Year in 2026

LAS VEGAS, NV / ACCESS Newswire / April 2, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported preliminary unaudited results for year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.

2025 Financial Highlights

• 2025 net revenue is expected to increase 45% to a record $4.5 million, with the increase due to the merger with Gummy USA, continued technological innovation, product line and distribution channel expansion, and strengthening direct-to-consumer and retail sales. Existing operations generated net revenue growth of approximately 25%.

• Direct-to-consumer product subscriptions increased 47% and Amazon "Subscribe & Save" customers increased 36% in 2025. Subscription customer growth continued to expand the company's recurring revenue stream and increase customer lifetime value while enhancing customer communications and retention.

2025 Operational Highlights

• At the beginning of the fourth quarter, completed the strategic merger with Florida-based Gummy USA^™, a leading developer and advanced manufacturer of precision-dosed nutraceutical gummies. The merger added Gummy USA's HACCP, GMP-certified and FDA-registered manufacturing facility expanded Healthy Extracts' vertical integration of R&D, outsourced manufacturing, marketing and distribution. Combined with Healthy Extracts' existing exclusive delivery systems (gel-packs and functional drinking straws), Gummy USA has unlocked a third specialized product development and marketing channel comprised of precision-dosed gummies for the nutraceutical and pharmaceutical markets.

• The Gummy USA Florida manufacturing facility and in-house R&D has begun to accelerate Healthy Extracts' overall product development and manufacturing process, enhance gross margins, and substantially strengthen the company's IP portfolio.

• Don Swanson, seasoned entrepreneur and manufacturing engineer and Gummy USA founder, was appointed CEO and chairman of Healthy Extracts. He further strengthened the management team as a recognized innovator in the fast-growing $13 billion global gummy supplement market. He invented and developed advanced, patent-pending white-label and private-label manufacturing solutions tailored for the health & wellness and pharma markets.

• Announced major 6 million nutraceutical gummy follow-on order from a woman's health nutraceutical leader. The gummies address a specialized need and were formulated under the guidance of the client's team of top-rated doctors, clinical professors and healthcare professionals, including board-certified internists, best-selling authors and leaders in family medicine.

• Launched STAT10, a revolutionary heart health formulation containing CoQ10, Berberine and Citrus Bergamot SuperFruit^™. The product expanded Healthy Extracts' addressable market beyond general heart health to supporting the unmet nutritional needs of 40 million existing statin users in the U.S. Clinically formulated to support nutrients inhibited by statins, STAT10 addresses the common side effects of muscle and joint pain, weakness and tiredness often associated with statins. STAT10 ingredients have been shown in clinical research to support heart health and the nutrients inhibited by statins.

• Launched 4Sleep, a natural, science-based healthy sleep formulation specially designed to support deeper, more restorative rest.

• Introduced the WHITNEY JOHNS^™ Gut Health Straw^™, the world's first fiber prebiotic and probiotic delivery straw. The innovative product was developed in partnership with fitness influencer and health advocate, Whitney Johns. Designed for maximum convenience and effectiveness, the product enables consumers to easily enjoy the gut health benefits of a naturally flavored, sugar-free prebiotic and probiotic blend by simply sipping a straw-no pills, powders or hassles. The product targets the fast-growing digestive health products market that is expected to more than double to $105 billion by 2033, according to Precedence Research.

• Expanded partnership with Gelteq Limited (NASDAQ:GELS), the clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and sports. Building upon the success of a co-developed product line of on-the-go gel-pack products, Healthy Extracts has become Gelteq's exclusive North American manufacturing, storage, shipping and fulfillment partner. The deeper collaboration is expected to reduce fulfillment costs and unlock higher margin sales opportunities.

• Maintained top three category ranking on Amazon.com, with the strong sales and customer acquisition performance due to the company's highly optimized sales and marketing strategies.

Management Commentary

"In the final quarter of 2025, we achieved record-setting net revenues for the fifth quarter in a row, with this driving another record year,' stated Healthy Extracts CEO and Gummy USA founder, Don Swanson.

"Our expected 45% year-over-year increase in net revenues, with 25% attributed to organic growth, reflects another M&A win along with strengthening performance across our direct-to-consumer and retail channels. Altogether, the year demonstrated how our well-tuned growth strategies continue to produce outsized results.

"During the year we also advanced the development of several new products and technologies across new categories, including products featuring our new fiber drinking straw and precision-dosed gummy manufacturing technologies. The commercial launch of these products benefits from the strategic cross promotion across our growing customer base and distribution channels.

"Our successful merger with Gummy USA last fall has been a strong catalyst for the transformation of our company, enabling us to execute on new growth strategies designed to expand our addressable market and strengthen our competitive position.

"This has involved intensifying our focus on our long-term strategic evolution toward leadership in Nutra Pharma technologies. Our operating performance in the first quarter is expected to remain consistent with the previous quarter and up dramatically year-over-year-all firmly in line with our growth plans and capital allocation priorities.

"Since the beginning of the year, we have been making great strides in our evolution into becoming a diversified platform addressing the high-growth, high-margin Nutra Pharma and Health & Beauty sectors.

"For the $636 billion health and beauty category, we enjoy tremendous opportunities to leverage our formulation capabilities, new manufacturing platform, and proprietary delivery technologies for new skin, hair and nail products, as well as broader health and wellness applications.

"Based upon our current commercial initiatives that include extensive new B2B customer engagement and product development, we see this category providing highly attractive opportunities to generate annualized revenue of more than $20 million by year end-or more than 4x above our current level. We believe this outlook is well supported by our current manufacturing facility and distribution capacity.

"We have also been making great strides in our clinical initiatives, acquiring FDA Pharma approval, clinical study readiness, and the development of regulatory property opportunities. We expect these efforts to support future product differentiation, scientific validation, and broad commercial adoption.

"Key to these efforts are our unique precision dose manufacturing capabilities and exclusive licensed delivery systems, We believe these provide valuable differentiation within the nutraceutical, Nutra Pharma and functional wellness markets.

"Through our advanced dosing technologies, proprietary gummy and gel-based delivery systems, and other exclusive oral delivery formats, we continue to position Healthy Extracts for success in health science, manufacturing innovation, and scalable commercialization.

"We believe we remain on track to further enhance shareholder value with our planned Nasdaq uplisting, with the Gummy USA merger and favorable capital structure helping us meet Nasdaq's listing requirements. We see the listing providing greater liquidity, institutional investor participation, more favorable M&A transactions, a higher valuation, and enable us to attract great new talent to our team. We see all of these positive elements coming into play as we work to make 2026 another stellar year for Healthy Extracts."

2026 Financial Outlook

Based on existing customer commitments and anticipated growth in order flow, the new Gummy USA unit is projected to generate additional substantial revenue growth in 2026, with its manufacturing facility potentially reaching its $20 million annual revenue production capacity during the year. This compares to $4.5 million in overall net revenue for the full year of 2025, for a potential increase of more than 344%.

New products across new categories and formats launched over the past year are expected to continue to drive growth with greater profitability (excluding non-cash-based expenses). New product launches are expected to benefit from the broad market channels the company has strategically invested in and developed over the last several years.

The company plans to drive future growth by reinvesting its cashflow and profits into new product development, sales and marketing, greater manufacturing capacity, potential acquisitions, and the further expansion of its distribution and sales channels.

Preliminary Results

The preliminary unaudited results presented in this press release are estimates only and are subject to revision until the company officially reports its audited 2025 results to be filed in Form 10-K with the SEC.

About Healthy Extracts "Live Life Young Again"

Healthy Extracts Inc. (OTCQB:HYEX) is a leader in nutraceutical innovations and precision dose gummy manufacturing. It develops, manufactures and markets proprietary, science-based supplements for brain, heart, and gut health. The platform enables clinically tested formulas and exclusive partnerships that deliver wellness solutions with measurable consumer and shareholder value.

The company's Gummy USA^™ subsidiary is a leading developer and manufacturer of precision-dosed nutraceutical and pharmaceutical-grade gummies. Its exclusive licensing proprietary patent-pending SureDose^™ technology delivers superior safety, efficacy and compliance for white and private label customers.

Healthy Extracts wholly owned subsidiaries, BergametNA^™ and Ultimate Brain Nutrients^™ (UBN), offer nutraceutical natural heart and brain health supplements. BergametNA products are the only heart health supplements distributed in North America containing Citrus Bergamot SuperFruit^™, the only superfruit with the highest known concentration of polyphenols and flavonoids.

Healthy Extracts has exclusive agreements for other innovative oral delivery systems that include Gelteq gel-packs and the Gut Health Straw, both of which provide superior bioavailability and ultimate consumer convenience.

To learn more, go to: healthyextractsinc.com, bergametna.com, tryubn.com or gummyusa.com.

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2025, and future periodic reports filed with the U.S. Securities and Exchange Commission (SEC). All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only to the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Food & Drug Administration Disclosure

The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Gummy USA ^™, BergametNA^™, Ultimate Brain Nutrients^™, UBN^™, Citrus Bergamot SuperFruit^™ and F4T^® are trademarks and registered trademarks of Healthy Extracts^™ Inc.

Company Contact

Duke Pitts, President & COO
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact

Investor Contact

CMA Investor Relations
Tel (949) 432-7554
Email contact

SOURCE: HEALTHY EXTRACTS INC.

View the original press release on ACCESS Newswire

FAQ

What preliminary 2025 revenue did Healthy Extracts (GELS) report on April 2, 2026?

The company reported preliminary 2025 net revenue of $4.5 million, a 45% increase year-over-year. According to the company, the rise was driven by the Gummy USA merger, product launches, and expanded direct-to-consumer and retail channels.

How much of Healthy Extracts' 2025 growth was organic versus from M&A for GELS?

Approximately 25% of 2025 growth was organic, with the remainder from the Gummy USA merger. According to the company, organic gains came from expanded subscriptions, Amazon performance, and retail sales.

What manufacturing capacity outlook did Healthy Extracts (GELS) give for 2026?

The company projected Gummy USA's facility could reach $20 million annual revenue in 2026, up from $4.5 million in 2025. According to the company, this reflects existing customer commitments and anticipated order flow.

What new products did Healthy Extracts (GELS) highlight in the 2025 results?

Highlighted launches include STAT10 (heart health), 4Sleep (sleep support), and the WHITNEY JOHNS Gut Health Straw. According to the company, these expand addressable markets and cross-promote across channels.

Are Healthy Extracts' 2025 results final and audited for GELS?

No, the results are described as preliminary unaudited estimates and may change. According to the company, audited 2025 results will be filed in a Form 10-K with the SEC.